ORCID Profile
0000-0002-6554-0169
Current Organisation
Massachusetts General Hospital
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Frontiers Media SA
Date: 10-01-2020
Publisher: Wiley
Date: 25-03-2020
DOI: 10.1111/FEBS.15279
Publisher: Wiley
Date: 13-06-2018
Publisher: Frontiers Media SA
Date: 13-06-2016
Publisher: Frontiers Media SA
Date: 09-08-2016
Publisher: Springer Science and Business Media LLC
Date: 28-08-2018
DOI: 10.1038/S41467-018-05572-Z
Abstract: In transplantation, donor dendritic cells (do-DCs) initiate the alloimmune response either by direct interaction with host T cells or by transferring intact donor MHC to host DCs. However, how do-DCs can be targeted for improving allograft survival is still unclear. Here we show CD103 + DCs are the major do-DC subset involved in the acute rejection of murine skin transplants. In the absence of CD103 + do-DCs, less donor MHC-II is carried to host lymph nodes, fewer allogenic T cells are primed and allograft survival is prolonged. Incubation of skin grafts with the anti-inflammatory mycobacterial protein DnaK reduces donor MHC-II on CD103 + DCs and prolongs graft survival. This effect is mediated through IL-10-induced March1, which ubiquitinates and decreases MHC-II levels. Importantly, in vitro pre-treatment of human DCs with DnaK reduces their ability to prime alloreactive T cells. Our findings demonstrate a novel therapeutic approach to d en alloimmunity by targeting donor MHC-II on CD103 + DCs.
Location: Brazil
Location: United States of America
No related grants have been discovered for Thiago J Borges.